Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations

PurposeTo assess the quality of life of glaucoma patients under medical therapy with different prostaglandin analogs.MethodsA cross-sectional study of consecutive glaucoma patients was designed. We assessed the patients’ quality of life through the Brazilian 25-question version of the National Eye Institute Visual Functioning Questionnaire, comprising 12 subscales (general health, general vision, ocular pain, near vision, distance vision, social function, mental health, role limitations, dependency, driving, color vision, and peripheral vision) and a total composite score. Clinical features, including current medical treatment, were obtained from each patient’s medical record. Three groups of patients were identified according to the prostaglandin in use: bimatoprost, latanoprost, or travoprost. The main outcome measures were: mean score in each subscale and mean total composite score.ResultsThe mean total composite score for the whole group was 70.60. The bimatoprost, latanoprost, and travoprost groups had the following mean composite scores, respectively: 56.56, 77.36, and 71.08 (P = 0.001, analysis of variance [ANOVA]). Latanoprost and travoprost results were similar, and both were superior to bimatoprost. Most subscales had similar results. The subscale with the lowest score for all groups was general health. Groups were homogenous and comparable.ConclusionThere is a difference in the quality of life between glaucoma patients using prostaglandin analogs. It seems that bimatoprost users have lower QoL when compared to latanoprost and travoprost users.

show abstract

“…In the literature, travoprost reportedly has efficacy and tolerability results similar to those of the other two prostaglandins. 17 …”

Section: Discussionmentioning

confidence: 99%

Quality of life of glaucoma patients under medical therapy with different prostaglandins

Guedes¹,

Guedes²,

Freitas³

et al. 2012

OPTH

View full text Add to dashboard Cite

show abstract

“…Latanoprost, travoprost and one other PGF 2α analog, unoprostone isopropyl are currently being used clinically (Fig. 3 ) [26, 36, 37]. Latanoprost and travoprost undergo facile hydrolysis by esterases present in cornea to biologically active latanoprost acid and travoprost acid respectively.…”

Section: Ocular Prodrug Strategiesmentioning

confidence: 99%

“…Latanoprost and travoprost undergo facile hydrolysis by esterases present in cornea to biologically active latanoprost acid and travoprost acid respectively. Cornea slowly releases latanoprost acid into anterior parts of the eye [36]. The maximum concentration of latanoprost acid has been detected in aqueous humour 1-2 hrs after topical application [38].…”

Section: Ocular Prodrug Strategiesmentioning

confidence: 99%

Prodrug Strategies in Ocular Drug Delivery

Barot

Bagui²,

Gokulgandhi³

et al. 2012

View full text Add to dashboard Cite

Poor bioavailability of topically instilled drug is the major concern in the field of ocular drug delivery. Efflux transporters, static and dynamic ocular barriers often possess rate limiting factors for ocular drug therapy. Different formulation strategies like suspension, ointment, gels, nanoparticles, implants, dendrimers and liposomes have been employed in order to improve drug permeation and retention by evading rate limiting factors at the site of absorption. Chemical modification such as prodrug targeting various nutrient transporters (amino acids, peptide and vitamin) has evolved a great deal ofintereSt to improve ocular drug delivery. In this review, we have discussed various prodrug strategies which have been widely applied for enhancing therapeutic efficacy of ophthalmic drugs. The purpose of this review is to provide an update on the utilization of prodrug concept in ocular drug delivery. In addition, this review will highlight ongoing academic and industrial research and development in terms of ocular prodrug design and delivery.

show abstract

“…Numerous studies have compared the action of different anti-glaucoma agents either singly or in combination. [ 4 5 6 7 8 9 ] When treating primary open-angle glaucoma, PGAs, beta blockers and CAIs are widely used as first-line agents (POAG). This occurs by either increasing tissue permeability or by acting on episcleral vessels, which are responsible for increasing the outflow from the uveoscleral system.…”

Section: Introductionmentioning

confidence: 99%

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma

Agarwal

Tayal

Gautum

2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Aim and Objective: To compare the efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in the treatment of primary open-angle glaucoma Design: Prospective, randomized, comparative, interventional study Setting: Tertiary eye care centre. Material and Method: The present study was a comparative study carried out on patients visiting OPD of Ophthalmology Department and diagnosed with primary open-angle glaucoma. Group 1 (n-30 BT) received brinzolamide1% and timolol0.5% fixed combination eye drops, and Group 2 (N-30 DT) patients received dorzolamide2% and timolol0.5% fixed combination eye drops. A complete ophthalmic examination was performed, including Goldmann applanation tonometry. IOP was measured twice daily (9 AM and 4 PM). The patients were evaluated at 2, 4, 8, and 12 weeks. IOP was measured at follow-up. Side effects and tolerability of both drugs were assessed, and patient preference for drugs was noted Results: Mean reduction in morning IOP was significantly more in Group 1 than in Group 2 at 8 weeks and 12 weeks (p < 0.05). Mean reduction in evening IOP was significantly more in Group 1 than in Group 2 at all follow-ups (p < 0.05) Conclusion: Brinzolamide1% + timolol0.5% fixed drug combination is more preferred and effective in lowering IOP than dorzolamide2% + timolol0.5% fixed drug combination in patients of primary open-angle glaucoma.

show abstract

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations

Cited by 6 publications

References 40 publications

Quality of life of glaucoma patients under medical therapy with different prostaglandins

Quality of life of glaucoma patients under medical therapy with different prostaglandins

Prodrug Strategies in Ocular Drug Delivery

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma

Contact Info

Product

Resources

About